Get the Stockscreener App
2.255
4.15%
0.085
Aclaris Therapeutics Inc stock is traded at $2.255, with a volume of 673.21K.
It is up +4.15% in the last 24 hours and up +89.92% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
See More
Previous Close:
$2.17
Open:
$2.18
24h Volume:
673.21K
Relative Volume:
1.33
Market Cap:
$160.88M
Revenue:
$31.25M
Net Income/Loss:
$-88.48M
P/E Ratio:
-1.4548
EPS:
-1.55
Net Cash Flow:
$-79.63M
1W Performance:
+32.16%
1M Performance:
+89.92%
6M Performance:
+66.18%
1Y Performance:
-57.91%
1-Day Range:
$2.15
$2.285
1-Week Range:
$1.65
$2.285
52-Week Range:
$0.5902
$5.705
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat
Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat
Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World
Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex
American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena
Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily
Accel Entertainment CEO sells shares worth over $49,000 By Investing.com - Investing.com UK
Arch Capital Group (ACGL) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright - MarketBeat
Meeder Advisory Services Inc. Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - Defense World
William Blair Investment Management LLC Sells 17,390 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Arch Capital Group (NASDAQ:ACGL) Sets New 1-Year High at $114.69 - MarketBeat
(ACEL) Long Term Investment Analysis - Stock Traders Daily
Analyzing Axcelis Technologies Inc (ACLS) After Recent Trading Activity - Knox Daily
Quest Partners LLC Cuts Stake in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Financial Metrics Exploration: Understanding Acrivon Therapeutics Inc (ACRV) Through Ratios - The Dwinnex
Market Watch: Aclarion Inc (ACON)’s Noteworthy Drop, Closing at 0.18 - The Dwinnex
Citi lifts Accenture stock price target on growth prospects - Investing.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Analysts - MarketBeat
Aclaris Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - Yahoo Finance
Quest Partners LLC Grows Position in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
Arch Capital Group (ACGL) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Accenture (ACN) Rises Higher Than Market: Key Facts - Yahoo Finance
AstraZeneca PLC ADR rises Monday, outperforms market - MarketWatch
Market Momentum: Astrazeneca plc ADR (AZN) Registers a -0.87 Decrease, Closing at 78.27 - The Dwinnex
Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks
Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg - TipRanks
ICA Group Wealth Management LLC Decreases Stock Position in Accenture plc (NYSE:ACN) - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Lifted to Strong-Buy at StockNews.com - Defense World
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclaris Therapeutics Inc Stock (ACRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
| Leonard Braden Michael | 10% Owner |
Jul 05 '24 |
Buy |
1.15 |
123,017 |
141,334 |
13,447,969 |
| Leonard Braden Michael | 10% Owner |
Jul 02 '24 |
Buy |
1.14 |
86,092 |
98,489 |
13,181,664 |
0.65%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):